Ennov teams up with CloudScientific to expand in China

By AI, Created 5:25 PM UTC, May 19, 2026, /AGP/ – Ennov has formed a strategic partnership with China-based CloudScientific to distribute its compliance platform and services in the Chinese life sciences market. The deal aims to help local companies connect regulatory, quality, clinical and pharmacovigilance workflows while meeting both domestic and global compliance demands.

Why it matters: - The partnership gives Ennov a local route into China through a provider with R&D digitalization expertise and an established customer base. - Chinese life sciences companies are under growing pressure to manage compliance, data and operations more efficiently while meeting expectations from agencies including NMPA, FDA, EMA and PMDA. - The collaboration is designed to help companies move away from fragmented systems and toward a single operating model that can scale globally.

What happened: - Ennov announced a strategic partnership with CloudScientific, a China-based provider of R&D digitalization solutions. - CloudScientific will act as Ennov’s distribution and services partner in China. - The partnership was announced May 19, 2026. - Ennov is a global provider of unified software for Regulatory, Quality, Clinical and Pharmacovigilance in life sciences. - CloudScientific will provide local access to the platform, plus implementation, support and consulting services.

The details: - CloudScientific was founded in 2009. - CloudScientific supports more than 1,500 biopharmaceutical and academic clients in China. - CloudScientific’s portfolio covers drug design, cheminformatics, bioinformatics and preclinical to clinical data management. - Ennov’s platform uses a shared foundation across Regulatory, Quality, Clinical and Pharmacovigilance. - Ennov says that structure can reduce duplication, improve traceability and connect workflows across functions. - The platform includes AI capabilities that automate selected tasks while maintaining compliance and data integrity. - Customers can manage Regulatory activities including RIM, eDMS, publishing and IDMP alongside Quality and Clinical processes in one environment. - Ennov’s solutions are built for regulated life sciences environments.

Between the lines: - The partnership pairs a global compliance software vendor with a local operator that already serves Chinese R&D users. - For Ennov, the deal likely lowers market-entry friction in China by leaning on CloudScientific’s relationships and implementation experience. - For CloudScientific, the partnership expands its portfolio with a unified compliance platform that may appeal to customers seeking international scalability. - Ennov’s emphasis on local market fit signals that China expansion depends on more than software features.

What they said: - “China has an incredibly dynamic life sciences market, and we know that success there depends on more than software,” said Olivier Pâris, founder and CEO of Ennov. “It takes local knowledge, trusted relationships, and a clear understanding of how teams work day to day.” - Pâris said the partnership should help Chinese life sciences companies connect processes, support compliance and grow with confidence. - Lin Jiancheng, CEO of CloudScientific, said Ennov’s unified architecture strengthens CloudScientific’s portfolio and gives Chinese clients access to modern tools that support compliance and long-term growth.

What’s next: - CloudScientific will begin distributing and supporting Ennov’s platform in China. - The partnership is intended to help Chinese life sciences organizations align more closely with international standards while keeping flexibility for a complex regulatory environment. - Ennov said the agreement fits its broader strategy of supporting life sciences companies globally with software that can adapt to local market needs.

The bottom line: - Ennov is betting that a local partner with deep R&D and regulatory know-how can accelerate adoption in China without sacrificing the unified compliance model it sells globally.